导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -14.47% | 4075/4773 |
| 近一周 | -2.90% | 3347/5462 |
| 近一月 | -1.24% | 888/5421 |
| 近一季 | -1.30% | 970/5209 |
| 近半年 | -6.61% | 3112/4920 |
| 近一年 | -13.45% | 3607/4366 |
| 近两年 | 29.52% | 2290/2954 |
| 近三年 | 13.28% | 1674/2253 |
| 成立以来 | 32.61% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-15.43% 4713/4961 |
3.47% 2943/5312 |
- - |
- - |
| 2025 | 9.66% 2859/4813 |
-6.17% 3342/3635 |
6.26% 473/4076 |
7.96% 3426/4524 |
1.88% 1174/4813 |
| 2024 | 31.96% 89/3463 |
-3.57% 1523/2808 |
-4.96% 1602/3014 |
42.51% 48/3129 |
1.03% 1131/3463 |
| 2023 | 0.61% 402/2656 |
2.70% 1312/2280 |
-0.66% 398/2385 |
6.50% 71/2515 |
-7.41% 2139/2655 |
| 2022 | -19.69% 884/2207 |
-15.79% 1071/1919 |
1.81% 1417/2016 |
-13.84% 981/2113 |
8.71% 258/2208 |
| 2021 | -6.52% 1011/1822 |
-11.88% 1144/1255 |
2.76% 989/1330 |
1.08% 457/1466 |
2.13% 691/1822 |
| 2020 | - - |
- - |
- - |
23.13% 31/1164 |
4.30% 850/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华中证800证保ETF VS. 长安沪深300非周期A(740101) |